Carpagnano, G. E., Resta, E., Povero, M., Pelaia, C., D’Amato, M., Crimi, N., . . . Barbaro, M. P. F. (2021). Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Nature Portfolio.
Chicago Style (17th ed.) CitationCarpagnano, Giovanna Elisiana, et al. Clinical and Economic Consequences of Switching from Omalizumab to Mepolizumab in Uncontrolled Severe Eosinophilic Asthma. Nature Portfolio, 2021.
MLA (8th ed.) CitationCarpagnano, Giovanna Elisiana, et al. Clinical and Economic Consequences of Switching from Omalizumab to Mepolizumab in Uncontrolled Severe Eosinophilic Asthma. Nature Portfolio, 2021.
Warning: These citations may not always be 100% accurate.